Sanofi-Synthelabo raises net profits 20.6 percent before Aventis tie-up
448727
Pharmaceutical group Sanofi-Synthelabo said it had increased net profit in the first half of the year by 20.6 percent from the same period last year to 1.138 billion euros (1.38 billion dollars).
732908
The company said fourth-quarter earnings rose 17 percent on higher sales of its Enbrel arthritis drug and Prevnar vaccine, but said generic competition would hit 2008 profit.
271064
Profits at the drugmaker increased 13 percent in the second quarter on higher sales of its arthritis drug and pneumonia vaccine.
167015
PARIS/LONDON  - Sanofi-Aventis shares rose on   Friday after a U.S. judge blocked further sales of generic   Plavix, but gains were capped as it warned cheap supplies of   the blood-thinner already in the market would hit 2006 profits.
509470
Pharmaceutical giant GlaxoSmithKline PLC reported a 21 percent increase in fourth-quarter net profit on Thursday, as additional offerings of its key anti-depressant drugs began to offset some of the generic competition that has curtailed the company's sales.
458557
An experimental drug from  Sanofi-Aventis, viewed as pivotal to the newly merged company's  future, showed good results in the largest clinical study of  the product to date.
139125
Genentech Inc. DNA.N on Wednesday  posted a 50 percent rise in quarterly profit and raised its  full-year earnings forecast on strong sales of its new colon  cancer drug, sending its shares higher in after-hours trading.
194383
Biotechnology company Genentech Inc  said on Monday its fourth-quarter profit rose 6.4 percent, but sales of several drugs, including blockbuster cancer drug Avastin, fell short of investor expectations, sending the company's shares lower.
181264
The biopharmaceutical company raised $108 million in an initial public offering that priced below a reduced forecast range.
346522
Cognizant Technology Solutions Corp. , which provides software services, on Monday reported a 21 percent increase in quarterly profit as it won more deals in Europe and in the health care industry.
745892
Sanofi-Aventis said on Friday that  U.S. regulators had approved wider use for its colon cancer  drug Eloxatin, lifting shares in the world's third-largest  pharmaceuticals group.
608900
Biotechnology company Genentech Inc   said on Monday its fourth-quarter profit rose 6.4  percent, but sales of several drugs, including blockbuster  cancer drug Avastin, fell short of investor expectations,  sending the company's shares lower.
312721
The biotechnology company reported fourth-quarter net income of $201.2 million on strong sales of its two leading drugs, Rituxan and Avonex.
229274
Genentech, the biotechnology company, posted a 41 percent increase in second-quarter profit on sales of its cancer drugs, continuing a positive earnings streak.
596137
Sanofi-Synthelabo said earlier this month it would push for 100 percent control of its former rival and newly-acquired subsidiary Aventis after the French Financial Market Authority confirmed the success of its ...
617822
The drug maker Sanofi-Aventis said its fourth-quarter profit fell 4.6 percent under pressure from European health care reforms and generic competition for its blockbuster medicines. It said earnings would be flat this year. The company, which is based in Paris, declined to comment on reports that it had discussed a merger with Bristol-Myers Squibb. Net profit at Sanofi-Aventis fell to 1.38 billion euros ($1.79 billion) in the fourth quarter from 1.44 billion euros a year earlier. Sales increased 5 percent, to 7.36 billion euros ($9.53 billion) from 7.01 billion euros.
267940
French insurance group AXA reported on Thursday an 18.0-percent rise in annual net profit to 5.1 billion euros (6.69 billion dollars), boosted by a strong performance from its life assurance activities.